Applications of umbilical cord blood mesenchymal stem cell medicine in promoting regeneration of knee joint cartilage

Abstract

The invention discloses applications of an umbilical cord blood mesenchymal stem cell medicine in promoting the regeneration of the knee joint cartilage. The umbilical cord blood mesenchymal stem cellmedicine comprises the following ingredients: 7-9 % of umbilical cord blood mesenchymal stem cells, 1-3 % of cartilage cells, 14-17 % of hyaluronic acid gel, 3-4 % of composite nanocellulose, 15-20 %of substrate liquid, 9-11 % of traditional Chinese medicine extract sustained release microspheres, the balance of micro vacuole lubricating liquid. A preparation method of the umbilical cord blood mesenchymal stem cell medicine comprises the following steps: (1) activating the composite nanocellulose by adopting heparin; (2) preparing the cell matrix; (3) preparing the traditional Chinese medicine extract sustained release microspheres; (4) preparing the micro vacuole lubricating liquid; and (5) preparing the reagent. In short, the technical scheme has the advantages that the ratio is reasonable, the injured cartilage tissue can be effectively repaired, the cure rate is high, and the pain feeling of patients is small. The technical scheme has positive significance in drug research and clinical treatment, and has good social and economic benefits.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an application of umbilical cord blood mesenchymal stem cell medicine in promoting knee joint cartilage regeneration. Background technique [0002] Cartilage damage is one of the most common knee disorders. Because cartilage has no blood vessels, nerves, and lymphatic tissues, and its nutrients mainly come from the synovial fluid of the knee joint, these histological characteristics make the self-repair ability of cartilage damage extremely limited. Traumatic cartilage damage can cause pain and swelling in the patient's joints. If not treated in time, it will accelerate the degeneration of the joints and cause more serious dysfunction. [0003] At present, the clinical treatment effect is not good, mainly to relieve the pain of patients and improve the function of knee joint. The reason is that the pathogenesis of cartilage injury is not clear. Drug therapy is m...

AI Technical Summary

Problems solved by technology

[0005] The use of umbilical cord mesenchymal stem cells in the prior art for therapeutic agents ensures the activity of umbilical cord mesenchymal stem cells as much as possible, so that it can promote the regeneration of damaged endogenous stem cells and differentiate into osteoblasts and chondrocytes. At the same time, it promotes the proliferation and replication of original chondrocytes, supplements and repairs damaged cartilage tissue; however, the protection of articular cartilage during treatment is relatively weak, which prolongs the treatment time and increases the pain of patients.

Images